
    
      Multi-center trial, Phase II, non-randomized, open-label, single-arm study with combined
      therapy of rituximab plus MG4101 in patients with indolent CD20-positive NHLs who has
      relapsed or refractory to prior chemotherapy or chemo-radiotherapy.
    
  